Eight blockbuster drugs are expected to generate over $3bn in peak sales each according to Novartis CEO Vas Narasimhan.

Intra-Cellular’s clinical-stage pipeline is promising, with pipeline agents under development for a wide range of neurological indications.

This month, pharma companies have announced plans to increase the prices of more than 250 branded drugs in the US.

Additionally, Daiichi Sankyo has partnered with MSD in a $22bn deal to advance ADCs targeting HER3, B7-H3, and CDH6. Each therapy in this pipeline utilises Daiichi Sankyo’s DXd technology. Enhertu and ...

Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment Leqembi (lecanemab-irmb) after the US Food and Drug Administration (FDA) ...

CEO Stéphane Bancel emphasised saving cash as integral in the company’s bid to parlay Covid-19 profits into future profitability.

Amgen presented data about its obesity drug at JP Morgan 2025, stating it hopes the once-monthly dosing will make it an attractive therapy.

There are many challenges small and medium sized businesses must overcome in clinical research. Credit: SFIO CRACHO via Shutterstock. The pharma sector is at a crossroads, with major challenges for ...

IFF Pharma Solutions is a winner in the Marketing category in the 2024 Pharmaceutical Technology Excellence Awards.

In a new webinar, industry experts explore how innovative technology and direct patient communication are transforming medication adherence in the UK.

Leading CRDMO Syngene is a Triple Category Award winner in the 2024 Pharmaceutical Technology Excellence Awards.

Mediar has entered into a global licensing agreement with Eli Lilly to progress MTX-463 into a Phase II trial for the ...